Targeting the resistance mechanism of AXL receptor tyrosine kinase overexpression, the combination of an AXL inhibitor (Anlotinib) and osimertinib has been employed to enhance antitumor effects by inhibiting the c-MET/MYC/AXL axis, thereby reversing osimertinib resistance in NSCLC[83]. The gene discussed is MET; the disease is non-small cell lung carcinoma.